Susana Ferreira Rocha

Susana Ferreira Rocha

Auto-generated profile, based on publicly available information

Susana Ferreira Rocha

Molecular Genetics of Angiogenesis Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
TATeresa Albendea-Gomez
Teresa Albendea-Gomez
SMSusana Mendoza-Tamajon
Susana Mendoza-Tamajon
RCRosana Castro-Mecinas
Rosana Castro-Mecinas
BEBeatriz Escobar
Beatriz Escobar
SRSusana Ferreira Rocha
Susana Ferreira Rocha
SMSilvia Martin-Puig
Silvia Martin-Puig
BACKGROUND: Hypoxia is associated with the onset of cardiovascular diseases including cardiac hypertrophy and pulmonary hypertension. HIF2 (hypoxia inducible factor 2) signaling in the endothelium mediates pulmonary arterial remodeling and subsequent elevation of the right ventricular systolic pressure during chronic hypoxia. Thus, novel therapeutic opportunities for pulmonary hypertension based on specific HIF2 inhibitors have been proposed. Nevertheless, HIF2 relevance beyond the pulmonary endothelium or in the cardiac adaptation to hypoxia remains elusive. Wt1 (Wilms tumor 1) lineage contributes to the heart and lung vascular compartments, including pericytes, endothelial cells, and smooth muscle cells. METHODS: Here, we describe the response to chronic hypoxia of a novel HIF2 mutant mouse model in the Wt1 lineage ( Hif2/Wt1 cKO [conditional knockout]), characterizing structural and functional aspects of the heart and lungs by means of classical histology, immunohistochemistry, flow cytometry, echocardiography, and lung ultrasound analysis. RESULTS: Hif2/Wt1 cKO is protected against pulmonary remodeling and increased right ventricular systolic pressure induced by hypoxia, but displays alveolar congestion, inflammation, and hemorrhages associated with microvascular instability. Furthermore, lack of HIF2 in the Wt1 lineage leads to cardiomegaly, capillary remodeling, right and left ventricular hypertrophy, systolic dysfunction, and left ventricular dilation, suggesting pulmonary-independent cardiac direct roles of HIF2 in hypoxia. These structural defects are partially restored upon reoxygenation, while cardiac functional parameters remain altered. CONCLUSIONS: Our results indicate that cardiopulmonary HIF2 signaling prevents excessive vascular proliferation during chronic hypoxia and define novel protective roles of HIF2 to warrant stable microvasculature and organ function.

13 December 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
IGIrene Garcia-Gonzalez
Irene Garcia-Gonzalez
SGStefano Gambera
Stefano Gambera
SRSusana F. Rocha
Susana F. Rocha
ARAlvaro Regano
Alvaro Regano
LGLourdes Garcia-Ortega
Lourdes Garcia-Ortega
RBRui Benedito
Rui Benedito
To understand gene function, it is necessary to compare cells carrying the mutated target gene with normal cells. In most biomedical studies, the cells being compared are in different mutant and control animals and, therefore, do not experience the same epigenetic changes and tissue microenvironment. The experimental induction of genetic mosaics is essential to determine a gene cell-autonomous function and to model the etiology of diseases caused by somatic mutations. Current technologies used to induce genetic mosaics in mice lack either accuracy, throughput or barcoding diversity. Here we present the iFlpMosaics toolkit comprising a large set of new genetic tools and mouse lines that enable recombinase-dependent ratiometric induction and single-cell clonal tracking of multiple fluorescently labeled wild-type and Cre-mutant cells within the same time window and tissue microenvironment. The labeled cells can be profiled by multispectral imaging or by fluorescence-activated flow cytometry and single-cell RNA sequencing. iFlpMosaics facilitate the induction and analysis of genetic mosaics in any quiescent or progenitor cell, and for any given single or combination of floxed genes, thus enabling a more accurate understanding of how induced genetic mutations affect the biology of single cells during tissue development, homeostasis and disease.

20 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSusana F. Rocha
Susana F. Rocha
LCLaura de la Bastida Casero
Laura de la Bastida Casero
MSMonika Spaczyńska-Kwiatkowska
Monika Spaczyńska-Kwiatkowska
Álvaro MacíasÁlvaro Macías
Álvaro Macías
YSYolanda Sierra-Palomares
Yolanda Sierra-Palomares
Eduardo OliverEduardo Oliver
Eduardo Oliver
Background: Pulmonary hypertension (PH) is a progressive vascular disease characterized by endothelial dysfunction, vascular remodeling and increased pulmonary vascular resistance. The β3-adrenergic receptor (β3-AR) has been implicated in cardiovascular regulation and cardioprotective mechanisms; however, its role in pulmonary vascular disease remains poorly understood. We investigated whether activation of β3-AR protects pulmonary endothelial function and prevents the development of pre-capillary PH. Methods: β3-AR expression was evaluated in pulmonary endothelium from patients with Chronic Obstructive Pulmonary Disease (COPD) and in murine models of hypoxia-induced PH. Genetic mouse models including β3-AR knockout (KO) and conditional β3-AR overexpression in endothelial cells (EC) or in smooth muscle cells (SMC), were used to determine cell-specific roles. Pharmacological activation of β3-AR was achieved using the selective β3-agonist mirabegron in hypoxia-induced PH mice and monocrotaline-induced PH rats. Pulmonary vascular reactivity and vasodilatory responses to β3-AR stimulation were evaluated by wire myography in isolated pulmonary arteries. Mechanistic studies were performed in human pulmonary artery endothelial cells (HPAEC) under hypoxic conditions, in human pulmonary arterial smooth muscle cells (HPASMC) and in endothelial nitric oxide synthase (NOS3) KO mice. Results: β3-AR was upregulated in pulmonary endothelium of COPD patients and mice exposed to chronic hypoxia. Genetic deletion of β3-AR aggravated PH, whereas endothelial-specific overexpression attenuated the disease phenotype, reducing right ventricular systolic pressure (RVSP), vascular remodeling and right ventricular (RV) hypertrophy. Activation of β3-AR with mirabegron improved pulmonary hemodynamics, reduced vascular remodeling and preserved RV function. β3-AR activation promoted endothelial nitric oxide synthase (eNOS)-dependent NO production, indirectly inhibiting SMC proliferation. Additionally, β3-AR activation improved mitochondrial fitness in endothelial cells by increasing uncoupling protein 2 (UCP2) expression, reducing reactive oxygen species (ROS) generation and preventing mitochondrial fragmentation. Conclusions: These findings identify endothelial β3-AR as a previously unrecognized regulator of pulmonary vascular homeostasis and provide a strong translational rationale for targeting the β3-adrenergic pathway in PH. Given that mirabegron is already approved for clinical use, our results support its repurposing as a therapeutic strategy for pre-capillary forms of PH.

4 November 2026 in Nature
Verified
Journal Article
Open access
PDF file
IGIrene Garcia-Gonzalez
Irene Garcia-Gonzalez
SRSusana F. Rocha
Susana F. Rocha
FOFilipa V. Oliveira
Filipa V. Oliveira
MSMaria S. Sanchez-Muñoz
Maria S. Sanchez-Muñoz
MLMariya Lytvyn
Mariya Lytvyn
RBRui Benedito
Rui Benedito
The vascular endothelial growth factor (VEGF) ligand and its main receptor VEGFR2 are considered to be essential for endothelial differentiation, proliferation, sprouting and survival 1 . Blood vessels cannot form in growing embryos or tissues when VEGF–VEGFR2 signalling is compromised in all cells 2,3 . The anti-VEGF antibody, which can block angiogenesis in cancer, wound healing or ischaemic diseases, is among the most widely used antibodies in the clinic. However, vascular resistance to anti-VEGF therapy has been reported 4,5 . Here we used iFlpMosaics and iSuRe –HadCre to induce and track genetic mosaics of endothelial cells (ECs) lacking VEGFR2 during the entire embryonic and postnatal development. These Vegfr2 -knockout ( Vegfr2 KO ) ECs adapted, proliferated normally and competed with wild-type cells over time, eventually forming a substantial portion of the vascular network in most organs. Vegfr2 KO ECs could not sprout during the first wave of angiogenesis in most tissues, because this process is highly VEGF-dependent and favours growth and mobilization of wild-type ECs. However, owing to their inability to respond to VEGF, Vegfr2 KO ECs became dominant in veins, which represented a long-term and continuous source of ECs for subsequent waves of VEGF-independent angiogenesis. Comparative single-cell RNA sequencing analysis of ECs with acute and long-term loss of VEGFR2 identified both common and organ-specific molecular mechanisms of adaptation and resistance to VEGF signalling loss. These included significant endothelial venousization and upregulation of ligands for VEGFR1 and VEGFR3. VEGFR1 only partially compensated for VEGFR2 loss in capillary ECs, whereas VEGFR3 compensated only in arterial ECs. Loss of the three VEGF receptors did not compromise venous growth. Notably, loss of the master regulator of venous development, NR2F2 (also known as COUP-TFII), significantly compromised expansion of Vegfr2 KO ECs. This work has implications for our understanding of the role of VEGF receptors in angiogenesis and demonstrates venousization as a mechanism of adaptation and resistance to VEGF signalling loss during angiogenesis.